FridayJul 23, 2021 12:00 pm

Researchers Compare COVID-19 to Other Respiratory Ailments

A group of researchers from the United States and Israel conducted a study that compared the disease progression and presentation between in-hospital patients suffering from COVID-19 with other respiratory ailments such as influenza. They discovered that coronavirus patients displayed a unique cardiorespiratory, immune and metabolic profile, noting that the disease’s severity was higher in comparison with other respiratory illnesses. The virus that causes the coronavirus, SARS-CoV-2, is a deadly and highly infectious virus. It has infected more than 190 million individuals and claimed more than 4 million lives across the globe, despite the effective control measures that were implemented in…

Continue Reading

ThursdayJul 22, 2021 12:17 pm

Study Finds That Focusing on the Past May Worsen Symptoms of Depression

A study recently published in the “Journal of Psychiatric Research” discovered that childhood trauma was linked to higher symptoms of depression, particularly in individuals who demonstrated a tendency to focus on the past instead of the future or even the present. Clinical depression, which is also known as major depressive disorder, is among the most common mental health conditions in the world. Childhood trauma is a typical feature of the disorder. The authors of the stud — Yingying Wang and colleagues — suggest that a personality factor may play a role in this association between depression and early trauma, noting…

Continue Reading

ThursdayJul 22, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event

Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the…

Continue Reading

WednesdayJul 21, 2021 2:34 pm

Teasing About Weight Could Trigger Eating Disorders

Prior studies have discovered that young individuals who experience discrimination or teasing about their weight have higher rates of eating disorders, self-harm, depression and social isolation. However, these studies have primarily focused on high-income and white participants, which makes it unclear whether these findings apply to other groups as well. This is why researchers from the School of Public Health at the University of Minnesota in Minneapolis conducted a study to examine the link between eating disorders and weight stigma in a socioeconomically and racially/ethnically diverse sample of more than 1,500 young individuals in the United States. An eating disorder…

Continue Reading

WednesdayJul 21, 2021 9:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA

CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the…

Continue Reading

TuesdayJul 20, 2021 2:36 pm

Adequate Levels of Vitamin D May Benefit Breast Cancer Patients

A new study has found that patients with breast cancer who have sufficient levels of vitamin D have better outcomes in the long term. Prof. Song Yao, who is the lead author of the study, suggests that maintaining adequate levels of vitamin D at the time of diagnosis and even after treatment may benefit breast cancer patients. The study’s results, which were presented at the American Society of Clinical Oncology’s virtual annual meeting, included findings that show that Black women had the lowest levels of vitamin D, which may explain why they had poorer outcomes after being diagnosed with breast…

Continue Reading

TuesdayJul 20, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory…

Continue Reading

MondayJul 19, 2021 1:30 pm

Study Finds Regular Physical Activity Boosts Brain Health in Growing Children

A recent study conducted by researchers from Boston Children’s Hospital has found that exercise assists in the organization of developing brains in growing children. The study discovered that physical activity was linked to more flexible, strong and efficiently organized brain networks. Dr. Caterina Stamoulis, who is the study’s lead, conducted an analysis of brain imaging data collected from an estimated 6,000 children between the ages of nine and ten. Stamoulis, who is also the head of the Boston Children’s Computational Neuroscience Laboratory, explained that the physical activity children engaged in didn’t matter as long as they were active. She conducted…

Continue Reading

MondayJul 19, 2021 11:22 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

Continue Reading

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb).  "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050